title: Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).
abstract: BACKGROUND: Biochemical marker combinations, including alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transpeptidase, and total bilirubin (all part of FibroTest) plus alanine aminotransferase (all part of ActiTest), are being developed as alternatives to liver biopsy in patients with chronic hepatitis C and other various chronic liver diseases. Considering this premise, the primary aim of this study was to assess the impact of meal intake on FibroTest and ActiTest results. Such studies are very important for patients, as many clinical errors have been related to the absence of baseline evidence. RESULTS: Intra-individual variation was assessed for the 6 above components and for FibroTest and ActiTest, by measuring time dependent variations before and one hour after a standard meal in 64 subjects. These consisted of 29 healthy volunteers and 35 patients with chronic liver diseases. Meal intake had no significant impact on any of the six components, or on FibroTest or ActiTest, as assessed by repeated measure variance analyses (ANOVA all p > 0.90); the Spearman correlation coefficient ranged from 0.87 (total bilirubin) to 0.995 (gamma-glutamyl transpeptidase). The coefficients of variation (CV) between fasting and postprandial measurements fluctuated for the six components from 0.09 (apolipoprotein A1) to 0.14 (alpha2-macroglobulin), and from 0.09 for FibroTest to 0.13 for ActiTest. In contrast, meal intake had a significant impact on triglycerides (ANOVA p = 0.01, CV = 0.65) and glucose (ANOVA p = 0.04, CV = 0.31). As for the prediction of liver injury, the concordance between fasting and postprandial predicted histological stages and grades was almost perfect, both for FibroTest (kappa = 0.91, p < 0.001) and ActiTest (kappa = 0.80, p < 0.001). CONCLUSIONS: The intra-individual variation of biochemical markers was low, and it was shown that measurements of FibroTest, ActiTest and their components are not significantly modified by meal intake. This fact makes the screening of patients at risk of chronic liver diseases more convenient.
authors.affiliation: Department of Hepato-Gastroenterology, Hôpital La Pitie-Salpétrière, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France. tpoynard@teaser.ff
authors.forename: Mona
authors.initials: M
authors.lastname: Munteanu
authors.forename: Djamila
authors.initials: D
authors.lastname: Messous
authors.forename: Dominique
authors.initials: D
authors.lastname: Thabut
authors.forename: Françoise
authors.initials: F
authors.lastname: Imbert-Bismut
authors.forename: Mathieu
authors.initials: M
authors.lastname: Jouys
authors.forename: Julien
authors.initials: J
authors.lastname: Massard
authors.forename: Annie
authors.initials: A
authors.lastname: Piton
authors.forename: Luminita
authors.initials: L
authors.lastname: Bonyhay
authors.forename: Vlad
authors.initials: V
authors.lastname: Ratziu
authors.forename: Bernard
authors.initials: B
authors.lastname: Hainque
authors.forename: Thierry
authors.initials: T
authors.lastname: Poynard